Your browser doesn't support javascript.
loading
A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting ß2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
Maleki-Yazdi, M Reza; Beck, Ekkehard; Hamilton, Alan L; Korducki, Lawrence; Koker, Paul; Fogarty, Charles.
Afiliação
  • Maleki-Yazdi MR; Division of Respiratory Medicine, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada. Electronic address: maleki.pccrc@on.aibn.com.
  • Beck E; Medical Department, Institut für Gesundheitsförderung, Rüdersdorf, Brandenburg, Germany.
  • Hamilton AL; Boehringer Ingelheim (Canada) Ltd, Burlington, Ontario, Canada.
  • Korducki L; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.
  • Koker P; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.
  • Fogarty C; Spartanburg Medical Research, Spartanburg, SC, USA.
Respir Med ; 109(5): 596-605, 2015 May.
Article em En | MEDLINE | ID: mdl-25829298
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Broncodilatadores / Doença Pulmonar Obstrutiva Crônica / Benzoxazinas / Agonistas de Receptores Adrenérgicos beta 2 Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Broncodilatadores / Doença Pulmonar Obstrutiva Crônica / Benzoxazinas / Agonistas de Receptores Adrenérgicos beta 2 Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article